Alveus Therapeutics Series A total to $197M
TL;DR
Alveus Therapeutics has completed a $197 million Series A financing to advance its obesity and metabolic disease therapies, including ALV-100 into Phase 2 trials. The funding, led by investors like New Rhein Healthcare, supports pipeline expansion and clinical development.
Tags
Alveus Therapeutics Series A total to $197M
Alveus Therapeutics Completes $197 Million Series A Financing to Advance Obesity and Metabolic Disease Therapies
Alveus Therapeutics Inc., a clinical-stage biotechnology company focused on next-generation therapies for obesity and metabolic diseases, has completed its Series A financing with a total of $197 million following a second closing, according to a January 2026 press release. The initial round in January 2026 secured $159.8 million, with the subsequent investment bringing the total to $197 million.
The financing, led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, includes participation from Sanofi Capital, Kurma Partners, Avego BioScience Capital, and other healthcare investors. Jan Van den Bossche of Andera Partners and Claudio Nessi of Omega Funds joined Alveus’ board alongside the second closing.
Proceeds will advance ALV-100, the company’s lead bifunctional GIPR antagonist/GLP-1R agonist, into Phase 2 trials, support Investigational New Drug (IND) filings for ALV-200 (a selective amylin receptor agonist), and expand its pipeline of oral and injectable therapies targeting metabolic disorders. The company emphasized its focus on durable weight management, improved tolerability, and long-term health outcomes, addressing limitations of existing treatments.
Alveus’ leadership team includes CEO Raj Kannan (formerly of i-Mab and Aerie Pharmaceuticals) and executives with extensive experience in metabolic disease drug development, including roles at Novo Nordisk, Eli Lilly, and Celgene.
The investment aligns with growing industry interest in obesity therapeutics, a sector marked by high unmet medical needs and significant market potential. Omega Funds, which has a history of backing life sciences innovations, highlighted its confidence in Alveus’ pipeline and global operational footprint spanning the U.S. and Denmark.
With this funding, Alveus aims to accelerate clinical development and establish a leadership position in metabolic disease innovation. The company remains headquartered in Philadelphia, with R&D operations in Copenhagen.
Second closing brings total Series A to $197 million: Initial $159.8 million raised in January 2026, with pipeline and investor details.
